These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19364498)

  • 1. Polymorphisms of MLH1 in benign prostatic hyperplasia and sporadic prostate cancer.
    Tanaka Y; Zaman MS; Majid S; Liu J; Kawakami K; Shiina H; Tokizane T; Dahiya AV; Sen S; Nakajima K
    Biochem Biophys Res Commun; 2009 Jun; 383(4):440-4. PubMed ID: 19364498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
    Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
    Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
    Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
    Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
    Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of DNA repair genes in prostate tumourigenesis in Indian males.
    Bansal A; Soni A; Rao P; Singh LC; Mishra AK; Mohanty NK; Saxena S
    Indian J Med Res; 2012 Oct; 136(4):622-32. PubMed ID: 23168703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
    Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
    Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
    Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
    Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
    DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between MLH1 -93 G>A polymorphism of DNA mismatch repair and cancer susceptibility: a meta-analysis.
    Pan XM; Yang WZ; Xu GH; Bai P; Qin HJ; Zhang LS; Zhai XD; Tang M; Deng W; Zhang L; Gao LB
    Mutagenesis; 2011 Sep; 26(5):667-73. PubMed ID: 21745804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
    Habuchi T; Suzuki T; Sasaki R; Wang L; Sato K; Satoh S; Akao T; Tsuchiya N; Shimoda N; Wada Y; Koizumi A; Chihara J; Ogawa O; Kato T
    Cancer Res; 2000 Jan; 60(2):305-8. PubMed ID: 10667581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of germline MLH1 alterations in familial prostate cancer.
    Fredriksson H; Ikonen T; Autio V; Matikainen MP; Helin HJ; Tammela TL; Koivisto PA; Schleutker J
    Eur J Cancer; 2006 Nov; 42(16):2802-6. PubMed ID: 16963262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
    Zambra FM; Biolchi V; Brum IS; Chies JA
    Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A MLH1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer.
    Nejda N; Iglesias D; Moreno Azcoita M; Medina Arana V; González-Aguilera JJ; Fernández-Peralta AM
    Cancer Genet Cytogenet; 2009 Sep; 193(2):71-7. PubMed ID: 19665066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of imperative polymorphisms of MLH1 gene in sporadic colorectal cancer.
    Milanizadeh S; Khanyaghma M; Haghighi MM; Mohebbi S; Damavand B; Almasi S; Azimzadeh P; Zali M
    Cancer Biomark; 2013 Jan; 13(6):427-32. PubMed ID: 24595079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Polymorphism of Mismatch Repair Genes and Susceptibility to Prostate Cancer.
    Khooshemehri P; Jamaldini SH; Ziaee SAM; Afshari M; Sattari M; Narouie B; Sotoudeh M; Montazeri V; Sarhangi N; Hasanzad M
    Urol J; 2020 May; 17(3):271-275. PubMed ID: 31953835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
    Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
    Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
    Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
    J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
    Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
    Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia.
    Tsuchiya N; Wang L; Horikawa Y; Inoue T; Kakinuma H; Matsuura S; Sato K; Ogawa O; Kato T; Habuchi T
    Int J Oncol; 2005 Jan; 26(1):225-31. PubMed ID: 15586244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.